REQUEST FOR PROPOSALS DEMONSTRATION PROJECTS IN OH-ALIVE 2014
|
|
- Horace Tobias Ward
- 6 years ago
- Views:
Transcription
1 REQUEST FOR PROPOSALS DEMONSTRATION PROJECTS IN OH-ALIVE 2014 RFP Issue Date: June 1, 2014 Letter of Intent Due Date: July 1, 2014 (4 chosen) Invited Proposal Due Date: August 15, 2014, 5:00 pm EST Awardees Announcement Date: October 1, 2014 (2 chosen) Description of Funding: The National Center of Regenerative Medicine (NCRM) is accepting proposals for funding of Demonstration Projects for the OH-Alive Innovator Platform: A Process and Manufacturing platform for Cell Therapy for the period November 1, 2014 January 31, Each project will have approximately 3 months to perform optimization cell culture runs. All data generated will be shared with the platform and principal investigator. New intellectual property developed for the project will be assigned to the submitting principal investigator s institution. We expect to complete at least 8 individual pilot Demonstration Projects by December Each project will be allocated $40,000 to cover supply and evaluation costs and each PI is asked to embed one part- or full-time employee (typically PhD level) towards the conductance of the process optimization, while their project is active in OH-Alive. Academic investigators are expected to leverage other project support (such as Federal Grants, Foundation support, other means) towards their respective project as it runs within the OH- Alive. An additional $20,000 can be allocated to any of the demonstration projects after completion based on its commercial merit and immediate potential for a clinical trial. Completion of the project is determined by either finishing sufficient experiments to optimize a manufacturing method or exhaustion of funds towards this goal. No funds will be used outside of the OH-Alive platform. About NCRM: The National Center of Regenerative Medicine (NCRM) is composed of investigators from Case Western Reserve University (CWRU), University Hospitals Case Medical Center (UHCMC), the Cleveland Clinic (CC), Athersys Inc, and The Ohio State University. NCRM s mission is to rapidly translate cutting-edge adult-derived stem cell technology into the clinical and commercial arenas. Currently ten different non-embryonic and two pluripotent stem cell types are being investigated in a range of therapeutic areas including cancer, musculoskeletal, orthopedic, cardiovascular, hematopoietic and neurodegenerative disorders. We encourage you to visit, as well as save to your favorites, our website Page 1 of 10
2 OH-Alive Platform Overview: The OH-Alive platform brings interested corporate and non-profit parties together in a truly shared effort, leveraging individual commitments, interests, and experience to advance new cell therapies to patients and enable new manufacturing intellectual property (IP) to be developed and buttress the clinical programs of both academic and for-profit companies. The platform consists of specific hardware that includes a dedicated innovation platform for determining process-specific parameter optimization for advanced cell culture. Integrated with this physical accelerator is the NCRM s Cellular Therapies Integrated Service (CTIS); a competency scaffold that is able to facilitate all aspects of a cell application from FDA consultancy, IND-filing support, help in filing for intellectual property regarding stem cell technologies, and to facilitate and guide researchers and clinicians with compliance matters involving the Institutional Review Board (IRB). Together, the vision for OH-Alive is to be a one-stop Stem Cell Innovator Platform that will enable companies, the academic researcher advancing newly discovered cell biology, and clinicians desiring to offer cutting-edge therapies to their patients, all to be better able to demonstrate that they can make a difference in the area of cell therapy. OH-Alive s goals are To transform medical therapy through the use of cells rather than drugs to heal tissues and organs To create the commercial and academic infrastructure in Ohio to establish a selfsufficient, vibrant industry of biotechnology and support services that are attractive to cell-therapy institutions across the US Through the Case Western Reserve University Technology Transfer Office, OH-Alive has dedicated support for managing and protecting new intellectual property (IP). OH-Alive s clients will receive the exclusive ability to benefit from commercialization outcomes emanating from utilization of the facility and OH-Alive will assign ownership to its clients any/all IP that is created as part of this service. Collaborative agreements to reduce feefor-service costs will be negotiated on a case basis but royalty stream or milestone payments will be added to this co-development situation. This gives clients flexibility, especially in the academic setting, and increased accessibility to this platform. Demonstration projects will be assumed to be paid in full and all IP transferred to the principal investigator. Of particular benefit for academic investigators and for-profit organizations is access to robotic and incubator equipment to facilitate rapid evaluation of multiple protocol parameters, analytical equipment for verification of cell type and performance, and administrative, technical and regulatory personnel, without having to duplicate resources. They will also have access to NCRM s existing competency in executing new cell therapies. OH-Alive staff will collaborate on grant applications, especially SBIR/STTR mechanisms. Together this will lead to the commercialization of cell therapies, not only resulting in advanced treatments for disease, but the establishment of multiple companies, with approved, commercial products. OH-Alive Demonstration Project Overview: The purpose of this RFP is to assist in the development of novel cell therapeutics and diagnostic platforms that will lead to both commercializable products and clinical interventions. Given the spectrum of potential uses of cells, this RFA will not restrict responses except to note that basic science projects without a readily identifiable and Page 2 of 10
3 immediate translational regenerative medicine application; pharmacological testing and assay development; and cell expansion projects that do not require testing and optimization would in general be non-responsive. Projects using cells of non-human origin are not considered. Demonstration projects which have strong commercialization potential, a clinical application strategy with a realistic timeline, are desired. Engagement of commercial partners or a stated entrepreneurial approach to the emerging technology will strengthen the application. Our staff can be approached to assist in expanding these options. Funds are to be used to offset the costs of optimization and validation of cell expansion, treatments, purifications and release criteria that would move product development substantially forward. Some funds could be used as needed to offset costs for using the Cellular Therapies Integrated Service (CTIS). NCRM s CTIS is a competency scaffold that is able to facilitate all aspects of a cell application from FDA consultancy, IND-filing support, help in filing for intellectual property regarding stem cell technologies, and to facilitate and guide researchers and clinicians with compliance matters involving Institutional Review Board (IRB). Confidentiality of product development will be maintained with appropriate documentation, as indicated in the application. Proprietary projects should submit applications with explicit statements of stating the need for confidentiality so reviewers and participants can sign confidentiality agreements (executed by the CWRU Technology Transfer Office). Description of Equipment Available: Project feasibility is determined by instrumentation compatibility, and we encourage interested investigators to read the platform capabilities below carefully, and, when in doubt, contact OH-Alive personnel to determine technical fit. The OH-Alive platform consists of an environmentally isolated and controlled X-Evo system (X-Vivo enclosure + Evo150 liquid handling instrumentation + carousel incubator) for manual and automated cell culturing, and a QuantStudio instrument set up with OpenArray capabilities for gene expression analysis. The X-Vivo enclosure is a modular solution replacing the more traditional clean room setting. It allows for complete environmental control of cellular conditions putting the cells rather than the scientist first. Oxygen, carbon dioxide, humidity and temperature can be controlled on a modular or global scale to eliminate cell shock during cell culturing and processing. Manual processing chambers and built-in incubators allow for manual cell expansion. A light microscope, centrifuge and cell counter are enclosed in the system to limit exposure to non-ideal conditions during basic cell evaluation procedures. Buffer chambers allow items to be introduced into the system with minimum particulates and contaminants. Licensed design of experiments (DoE) software is used to create an optimized experimental design to meet the desired outcomes for the project. Factors to be manipulated are entered into the program and an experimental design meeting the breadth of testing is generated. Resultant experimental data (gene and imaging) can then be entered back into the software for data analysis. Multivariate analysis from this software allows deep understanding of the experimental space, including sweet spot detection of a desired outcome using the input factors. The Evo liquid handling instrument along with the carousel incubator are also enclosed within the X-Vivo enclosure and allow for automated processing of a wide range of Page 3 of 10
4 experimental parameters as defined by DoE designs. The system is uniquely designed for optimization protocols exploring cell growth and differentiation conditions using complicated media compositions, including multi-stage differentiation. Barcode scanning allows for chain of custody tracking of plates and ultimately the experimental conditions within those plates. The automated system can handle cell culture plates ranging from 6 well up to highthroughput 96 well plates. For data analysis, the QuantStudio OpenArray platform (Life Technologies) is available to provide gene expression data. The Investigator can customize up to 56 genes to analyze for each experiment. These 56 genes will include internal standards and target genes. For a typical project, minimum custom orders consist of 10 OpenArray plates, each plate testing 48 samples x 56 genes. This allows each experiment to generate 26,880 gene expression data points which are imported back into the DoE software for data analysis of experimental conditions. OH-Alive staff can provide investigators with guidance on selecting appropriate genes to meet their experimental design or designing the OpenArray plate. Additional services can include use of a Cellomics ArrayScan High Content Analysis Reader to analyze the cell cultures for phenotypic characteristics via fluorescent markers, and nanofiber coating for 3D cell culture (Nanofiber Solutions). Example Demonstration Projects (not a comprehensive listing) Process optimization to determine optimal cell culture conditions of an existing biologic. A basic media formulation is currently being used; however this has never been optimized to increase culture stability, yield, or maximizing known performance parameters for the cellular material. Differentiation of a specific cell fate from a stem/stem-like state, where the resulting fate has clear clinical therapeutic relevance. The input material could be induced pluripotent stem cells, and the desired fate a more terminal one. Expansion and maintenance of adult primary cell cultures, otherwise difficult to grow ex-vivo. Identification and minimization of stray fate in human cell culture. Demonstration Project Process and Deliverables: Pipeline of OH-Alive projects: Academic or for-profit owned projects are evaluated based on preliminary data strength, commercialization ability, and match to the abilities of the OH-Alive platform Upon entry, process optimization will occur for a period of 3 months, which includes the validation of the production process New project IP will be filed with the aid of the OH-Alive personnel if applicable If desired, the OH-Alive can help facilitate the investigational new drug (IND) process If desired, OH-Alive and its business development partners can help with business startup, raising investment capital, and/or raising federal funds through R-type, or SBIR/STTR grants OH-Alive Deliverables: DoE-based experimentation to determine optimum cell culture conditions Other endpoints outlined and approved in the proposal Production of cellular material suitable for GLP studies Enable protocols to be transferred to a GMP production facility Study report that applies Quality by Design fundamentals Page 4 of 10
5 Development and validation of analytical methods required for release of cellular materials for human-use Support for preparation of IND documentation and regulatory guidance Business development support for spinout companies Important Dates: June 1, 2014 Issue RFP for Demonstration Project funding. July 1, 2014 Letter of Intent due date July 15, 2014 Invitation for full proposals sent to submitters August 15, 2014, 5:00 pm EST Proposals due to NCRM administration via to Michael Gilkey, October 1, 2014 OH-Alive Steering Board will choose awardees based scientific and commercialization merit and NCRM will announce awardees in a press release. October 2, 2014 Preparation for Demonstration project 1 will begin. November 1, 2014 Demonstration project 1 to commence. December 1, 2014 Preparation for Demonstration project 2 will begin. This date may change. January 1, 2015 Demonstration project 2 to commence. This date may change. Page 5 of 10
6 Proposal Guidelines and Format: This is an open and competitive process. Limited feedback from the OH-Alive Steering Board will be sent out to all applicants by December 1, (Refer to the section Proposal Format and Scoring Criteria as well as the Score Sheet.) All grants submitted will be reviewed. A brief summary of the review will be provided. Applicants must have investigator status: if commercial, be identified as a program leader, if academic be assistant professor or independent grant eligible project scientist or above. Collaborators must submit only one proposal; mirror proposals from multiple institutions will not be considered. Letters of Intent are due no later than 5 p.m. EST, July 1, will be invited for full proposals. Individuals may submit multiple LOIs, if desired. However, each proposal must be submitted separately and must match program criteria. Invited proposals are due no later than 5 p.m. EST, August 15, Proposals received after this date and time may not be considered for funding. Proposals must be submitted in electronic format using either Word or PDF files to Michael Gilkey, meg14@case.edu. Proposals not conforming to submission guidelines will not be considered for funding. Format: Proposals must use type size no smaller than 10 point and at least 1 margins The document must be saved in a Word or PDF titled as follows: your last name (period) first word of title (excluding articles, i.e. JONES.STEM). Proposal will have a maximum of 7 pages not including the NIH Approved Biographical Sketch and will be ordered as follows: 1. Title page. 2. Up to 2 pages background and results to date. 3. Up to 2 pages for program plan. 4. Up to 1 pages commercial potential, plan, timeline and milestones towards commercialization and commercial progress to date. 5. Up to 1 page matching funds and budget forecast detail note provisions for grantee funding of portions of the project 6. NIH Approved Biographical Sketch. 7. Departmental or corporate leadership signoff. This is essential to verify matching funds assignment to this project Confidential Information: We prefer to receive non-confidential information in both the LOI and full proposal (if invited). If it is necessary to include this information, please contact Michael Gilkey directly so appropriate steps can be taken to insure confidentiality. Page 6 of 10
7 Letter of Intent (LOI): The LOI is a one page description of the project you wish to submit. Describe the protocol you wish to optimize, including cell type, reagents, and specialized equipment needed to perform the studies. Will you provide the starting cells and/or reagents? Which cellular manufacturing parameters do you wish to test reagents, temperature, gas concentrations, etc? What tests, especially imaging markers, need to be run to determine the results of your differentiation process? What genes should be run on the Quantstudio OpenArray? Who from your group will be sent to the OH-Alive facility to oversee and direct the protocols? What are the expected outcomes of the work? If you are not sure about any of these questions, please indicate that so we can assist. Full Proposal Format and Scoring Criteria: The funding to be awarded in this program is underwritten by the Ohio Third Frontier. Its 10-year objectives with regard to this program are to: Build world-class research capacity. Support early stage capital formation and the development of new products. As such, projects funded by this program must be based on solid science and innovation and must have an identifiable and measurable clinical or commercial goal. To this end, project proposals must include the following information: Program background, scientific rationale, results and progress to date (2 pages): Information should include prior data and results that support the scientific plan being proposed, clinical rationale and significance, potential clinical need and impact, and competing work to be considered. Program Plan (2 pages): Describe in detail the protocol you wish to optimize, including cell type, reagents, and specialized equipment needed to perform the studies. Will you provide the starting cells and/or reagents? Which cellular manufacturing parameters do you wish to test reagents, temperature, gas concentrations, etc? What tests, especially imaging markers, need to be run to determine the results of your differentiation process? What genes should be run on the Quantstudio OpenArray 56 are available for each sample? Who from your group will be sent to the OH-Alive facility to oversee and direct the protocols? What are the expected outcomes of the work? Commercialization Potential, Plan and Progress to date (1 pages): What is the roadmap to commercialization for this technology? Has a Product been defined? Have any Intellectual Property filings (invention disclosure, patent, or license) been completed or planned? What is the regulatory pathway for this technology? Provide details for any substantive interactions with commercial entities or your current status as a commercial entity (basic company background and current investments). Matching Funds and Budget Forecast (1 page): Matching funds are highly encouraged though do not need to exceed personnel and travel costs for you or your lab person to help direct the experiments on site. Please provide detail on your matching funds to apply to the demonstration project; these might include personnel, supplies, and outside services. If you know the costs of the materials or services the platform will need to purchase for your project, please provide as much detail as possible so we can estimate the cost of your project. Please also remember, no funds will go outside of OH-Alive unless to a required core facility to support the project. Please send proposals and direct questions to meg14@case.edu or Page 7 of 10
8 Scientific and Commercialization Scoring Criteria: Scoring of submitted pilot grants will be performed by the OH-Alive Steering Board. This will be an expedited review but is based on current NIH criteria and each domain s weighting is shown out of a total of 100 points. Scientific Scoring (5 domains to be considered): Soundness of Scientific plan and Originality of the proposed Project: Is the proposed work based upon sound and well developed scientific principles? Is the experimental design and rational for the work proposed clearly articulated? Does the technology and approach represent a significant innovative step? (25 Points) Clinical Significance: Does this address a relevant clinical need? How effective are the current treatment options? What is the opportunity for this new technology to make a significant difference in either the standard of care, the total cost of care, or the patient experience? How many patients could be positively affected by this technology? (25 Points) Environment & Timeline: Is there adequate additional support through institutional resources, NCRM or other collaborators, complementary projects and funding sources? Is the project team the right one to get the work done? Does the on-site person working directly with the OH-Alive team have the ability to perform the proposed project within the time frame allotted? (25 points) Scope and Budget: Are the matching funds sufficient to run the project? Will the contribution made by an OH-Alive investment significantly accelerate the work and/or take it to a substantially higher level of value or fundability? (15 points) Leverage of NCRM, Ohio, or Regional Resources: Does this project involve collaborations that take advantage of or advance regional capabilities? Are downstream investments by other funding agencies likely if the project is successful? (10 points) Institutional or corporate commitment Commercialization Scoring (5 domains to be considered): Commercial ( Productization ) Feasibility: Are there existing disclosures, filings, issued patents or copyrights? Is it likely that the project will bear new patentable matter? How likely is it that a commercial product can be developed from this technology? Is there a product configuration anticipated? Are there significant hurdles to overcome from a cost, production, or regulatory standpoint? (30 points) Regulatory Feasibility: Is the proposed regulatory pathway correct and feasible to navigate by the applicant and its partners? What is the regulatory timeline and necessary pathway for safety and efficacy studies? How has the FDA handled products of this sort in the past? Is this a technology approach that the FDA has not encountered before? (25 points) How many years before this technology could be brought to market? Overall Market Impact: What is the size of the market? Is this a new platform technology or an incremental improvement over existing products? If the project is successful, does it have the potential to capture significant market share? (15 points) Page 8 of 10
9 Commercial Readiness: Have potential commercial partners been identified? Is there a relationship in place already? If applicant is a for-profit company, how well is the company positioned to commercialize the technology? (20 points) Disruptive index : To what extent will this technology create a fundamental shift in the market, versus simply creating an incremental improvement over existing technology? Will this development allow a dramatic market expansion or create access to a patient population that could not be served previously? Does it represent a dramatic cost reduction over current approaches? (10 points) Enthusiasm for each of these criteria will be graded by the reviewer based on the score guide below. Score Descriptor Additional Guidance on Strengths/Weaknesses 1 Exceptional Exceptionally strong with essentially no weaknesses 2 Outstanding Extremely strong with negligible weaknesses 3 Excellent Very strong with only some minor weaknesses 4 Very Good Strong but with numerous minor weaknesses 5 Good Strong but with at least one moderate weakness 6 Satisfactory Some strengths but also some moderate weaknesses 7 Fair Some strengths but with at least one major weakness 8 Marginal A few strengths and a few major weaknesses 9 Poor Very few strengths and numerous major weaknesses Minor Weakness: An easily addressable weakness that does not substantially lessen impact Moderate Weakness: A weakness that lessens impact Major Weakness: A weakness that severely limits impact Page 9 of 10
10 Project: PI: OH-Alive Demonstration Project Score Sheet Reviewer Score Comments Scientific Scoring (1-9) Soundness of Scientific plan and Originality of the project Clinical Significance Environment & Timeline Scope and Budget Leverage of NCRM/Regional Resources Scientific Composite Score Commercialization Scoring (1-9) Commercialization ( Productization ) Feasibility Overall Market Impact Regulatory Feasibility Commercial Readiness Disruptive Index Commercial Composite Score Overall Composite Score Reviewer Comments: Page 10 of 10
REQUEST FOR PROPOSALS DEMONSTRATION PROJECTS IN OH-ALIVE 2015
REQUEST FOR PROPOSALS DEMONSTRATION PROJECTS IN OH-ALIVE 2015 RFP Issue Date: April 8, 2015 Letter of Intent Due Date: May 8, 2015, 5:00 pm EST (4 chosen) Invitation for Full Proposals Sent to Submitters:
More informationTechnology Development Funding Program Round 3
Technology Development Funding Program Round 3 CWRU January 26, 2015 1 Program Overview NIH Center for Accelerated Innovations (NCAI) at Cleveland Clinic Mission to improve translation of basic science
More information2016 San Antonio Claude D. Pepper Older Americans Independence Center Pilot and Exploratory Study Core REQUEST FOR APPLICATIONS PILOT PROJECTS
2016 San Antonio Claude D. Pepper Older Americans Independence Center Pilot and Exploratory Study Core REQUEST FOR APPLICATIONS PILOT PROJECTS Mission: The major objective of the San Antonio Claude D.
More information2018 Call for Letters of Intent LOI Guidelines and Submission Instructions
2018 Call for Letters of Intent LOI Guidelines and Submission Instructions This call is being issued to support the development of SCN s funding application to the Networks of Centres of Excellence program.
More informationUniversity of California Center for Accelerated Innovation
University of California Center for Accelerated Innovation MICHAEL PALAZZOLO April 6, 2015 Outline CAI overview and introduction RFA and important dates Selection process Pre-application Finding help 2
More informationMARKEY CANCER CENTER STANDARD OPERATING PROCEDURES. SOP No.: MCC Type: Final
Page 1 of 11 MARKEY CANCER CENTER STANDARD OPERATING PROCEDURES SOP No.: MCC-002.03 Type: Final Title: Protocol Review and Monitoring Committee Functional Overview Approval Signature Date MCC Director
More informationNIH-RAID: A ROADMAP Program
NIH-RAID: A ROADMAP Program (Rapid Access to Interventional Development} A Program designed to facilitate the development of new therapeutics The NIH-RAID Pilot Program is intended to reduce some of the
More informationREQUEST FOR APPLICATIONS. MMRF Immunotherapy Networks of Excellence
REQUEST FOR APPLICATIONS MMRF Immunotherapy Networks of Excellence June 29, 2017 1. FUNDING OPPORTUNITY DESCRIPTION Purpose/Overall Goal: The Multiple Myeloma Research Foundation (MMRF) is issuing this
More informationThe SWOG ITSC Pilot Awards: Request for Application 2018 Announcement
The SWOG ITSC Pilot Awards: Request for Application 2018 Announcement SWOG formed an alliance with two premiere basic science research institutions - Cold Spring Harbor Laboratory (CSHL) and The Jackson
More informationCANCER CENTER SCIENTIFIC REVIEW COMMITTEE
CANCER CENTER SCIENTIFIC REVIEW COMMITTEE The Clinical Scientific Review Committee (SRC) at The Medical College of Wisconsin Cancer Center plays a vital role in protocol review and monitoring to ensure
More informationLimited Submission Review Instructions & Scoring Matrix NSF Scholarships in Science, Technology, Engineering, and Mathematics (S-STEM) 2019
Principal Investigator(s): BACKGROUND & INSTRUCTIONS A limited submission refers to a grant program that places a limitation on the number of proposal applications a single eligible entity can submit each
More informationPartnering with the NIH: Technology Transfer. Why partner?
Partnering with the NIH: Technology Transfer Jennifer Wong, M.S. Technology Development Coordinator National Institute of Mental Health Why partner? Enhance company s portfolio De-risks developing a technology
More informationStem Cell Research: Identifying emerging high priority policy issues
The state stem cell agency Stem Cell Research: Identifying emerging high priority policy issues Ellen G. Feigal, M.D. SVP, Research and Development National Cancer Policy Summit Washington, DC November
More informationCell and gene therapy: scaling up and moving to mass production
EDITORIAL Cell and gene therapy: scaling up and moving to mass production Nigel Whittle In order to fulfil the promise of cell therapy, it is important that manufacture of these therapies can be industrialized
More informationA Potential Innovative CMC Solution: Responding To Public Health Needs With An Accelerated Clinical Pathway A Vaccine Example
A Potential Innovative CMC Solution: Responding To Public Health Needs With An Accelerated Clinical Pathway A Vaccine Example January 2018 Natalie A. Christian Integrated Development and Supply Team Lead
More informationFebruary 15, Re: Docket No. FDA-2017-D-6159: Expedited Programs for Regenerative Medicine Therapies for Serious Conditions
February 15, 2018 Dockets Management Staff (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2017-D-6159: Expedited Programs for Regenerative Medicine
More informationCritically Evaluating the Benefits of Automation in Commercial- Scale Manufacture
AUTOMATION OF CELL AND GENE THERAPY MANUFACTURING: FROM VEIN TO VEIN INNOVATOR INSIGHT Critically Evaluating the Benefits of Automation in Commercial- Scale Manufacture Nina Bauer leads Lonza s Autologous
More informationNon-Dilutive Funding for Opportunities for CNS/PNS Related R&D
FreeMindGroup FreeMind Group @FreeMindGrp Non-Dilutive Funding for Opportunities for CNS/PNS Related R&D Jonathan H. Adalist Sr. Director, Business Development September 6, 2017 FreeMind Group FreeMind
More informationRecommendations for Strengthening the Investigator Site Community
Recommendations for Strengthening the Investigator Site Community October 2017 CTTI MISSION: To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials
More informationNanotechnology and Advanced Materials for more effective Healthcare
Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics
More informationA gateway to academic excellence for Biotech and Pharma
A gateway to academic excellence for Biotech and Pharma 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s patient centered, translational technology Engaging
More informationAdvancing Manufacturing for Advanced Therapies
Advancing Manufacturing for Advanced Therapies Peter Marks, MD, PhD Center For Biologics Evaluation and Research, FDA CASSS Cell & Gene Therapy Symposium July 10, 2018 Overview Cell and gene therapy products
More informationEvaluation & Decision Guides
SURGERY STRATEGIC CLINICAL NETWORK EVIDENCE DECISION SUPPORT PROGRAM Evaluation & Decision Guides 2014 Revision (v3) New ideas & Improvements Department of Surgery Evidence Decision Support Program Resource
More informationInnovative Medicines Initiative
Innovative Medicines Initiative EMA - EBE Regulatory Conference on ATMPs Salah-Dine Chibout, Novartis Global Head Discovery & Investigative Safety/ Global Head Preclinical Safety Therapeutic Areas IMI
More informationDecision Tree for selection of model agreements for collaborative commercial clinical research
Decision Tree for selection of model agreements for collaborative commercial clinical research 1 Research interactions involving industry, universities and the NHS Industry, universities and the NHS cooperate
More informationThis template is to be used by companies willing to submit an overview of relevant
Briefing book template for pharmaceuticals to support a multi-hta Early Dialogue (ED) December 13 th, 2013 This template is to be used by companies willing to submit an overview of relevant information
More informationIRB USE ONLY Approval Date: September 10, 2013 Expiration Date: September 10, 2014
Approval : September 10, 2013 Expiration : September 10, 2014 DESCRIPTION: You are invited to donate your leftover frozen eggs and/or ovarian tissues generated during your fertility preservation treatment
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationProduction Assistance for Cellular Therapies PACT
Production Assistance for Cellular Therapies PACT Traci Heath Mondoro, PhD NHLBI Bethesda, Maryland Renewed PACT Program Renewed January 15, 2010 Scope and size expanded Cell Processing Facilities (CPFs)
More informationUNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONFLICTS OF INTEREST
UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONFLICTS OF INTEREST I. PURPOSE To document the policy and procedures used by the University of Tennessee Graduate School
More informationVenture Philanthropy Models: The Leukemia & Lymphoma Society's Therapy Acceleration Program. A FasterCures Webinar June 19, 2013
Venture Philanthropy Models: The Leukemia & Lymphoma Society's Therapy Acceleration Program A FasterCures Webinar June 19, 2013 What is FasterCures? Founded in 2003, our mission is to save lives by saving
More informationEducation Critical to Stem Cell Therapy Pipeline
June 2016 Education Critical to Stem Cell Therapy Pipeline Don L. Gibbons Senior Science and Education Communication Officer ABOUT California Institute for Regenerative Medicine (CIRM) CIRM is California
More informationIRB USE ONLY Approval Date: September 10, 2013 Expiration Date: September 10, 2014
Approval : September 10, 2013 Expiration : September 10, 2014 DESCRIPTION: You are invited to donate your excess sperm and/or testicular biopsy material, as well as your somatic cells (ordinary body cells
More informationMARKEY CANCER CENTER CLINICAL RESEARCH ORGANIZATION STANDARD OPERATING PROCEDURES SOP No.: MCCCRO-P
Page 1 of 5 MARKEY CANCER CENTER CLINICAL RESEARCH ORGANIZATION STANDARD OPERATING PROCEDURES SOP No.: Title: Protocol Review and Monitoring Committee Revision: N/A Revision Date: N/A Functional and Administrative
More informationA GATEWAY TO ACADEMIC EXCELLENCE FOR BIOTECH AND PHARMA
A GATEWAY TO ACADEMIC EXCELLENCE FOR BIOTECH AND PHARMA Découpe 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s Patient centered, translational technology
More informationInnovation and Technology in Breast Cancer 2019 A research initiative from Breast Cancer Foundation NZ.
Request for Proposals Innovation and Technology in Breast Cancer 2019 A research initiative from Breast Cancer Foundation NZ. Overview Breast Cancer Foundation NZ (BCFNZ) is committed to funding research
More informationUCS PRE-AWARD PROCESS PROJECT DEVELOPMENT CHECKLIST
UCS PRE-AWARD PROCESS PROJECT DEVELOPMENT CHECKLIST You may find it helpful to consider the prompts below when you are developing your project proposal. Please remember that further support is available
More informationThe National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as a source of Non-Dilutive Funding
@FreeMindGrp FreeMind Group The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as a source of Non-Dilutive Funding FreeMind Group Webinar Jonathan Adalist FreeMind Group, LLC
More informationI. Company Information
Please fill out this form as completely as possible. Note: There is no fee to apply. Please send additional materials such as your pitch deck and executive summary to resi@lifesciencenation.com for us
More informationA new Model of Vaccine R&D Global Health Public Private Partnership : The Global Health Vaccine Center of Innovation (GHVCI)
A new Model of Vaccine R&D Global Health Public Private Partnership : The Global Health Vaccine Center of Innovation (GHVCI) Jean Lang avp R&D sanofi pasteur 9eme Rencontre Nationale des Directeurs de
More informationMRC Funding for Translational Research
MRC Funding for Translational Research Dr Tom Foulkes tom.foulkes@headoffice.mrc.ac.uk May 2011 Translational research - importance to the MRC Central to delivery of MRC s mission Recent favourable CSR
More informationA PMP Among PhDs: Applying Program Management to Biotechnology Research and Commercialization Speaker: Jill Almaguer, PE, MBA, PMP Company: Texas
A PMP Among PhDs: Applying Program Management to Biotechnology Research and Commercialization Speaker: Jill Almaguer, PE, MBA, PMP Company: Texas Heart Institute Website: www.texasheart.org, www.ccobtexas.org
More informationInformation Technology Services Project Management Office Operations Guide
Information Technology Services Project Management Office Operations Guide Revised 3/31/2015 Table of Contents ABOUT US... 4 WORKFLOW... 5 PROJECT LIFECYCLE... 6 PROJECT INITIATION... 6 PROJECT PLANNING...
More informationUNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONFLICTS OF INTEREST
UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONFLICTS OF INTEREST I. PURPOSE To document the policy and procedures used by the University of Tennessee Graduate School
More informationCompany Report Daring to be different
Company Report 2010 Daring to be different Daring to be different Galapagos has continued to follow its own unique path and is now a leading international biotechnology company. In our 2010 report, we
More informationWhat s New in GCP? FDA Draft Guidance Details FIH Multiple Cohort Trials
Vol. 14, No. 10, October 2018 Happy Trials to You What s New in GCP? FDA Draft Guidance Details FIH Multiple Cohort Trials While multiple, concurrently accruing patient cohorts in first-in-human (FIH)
More informationFor personal use only
10 April 2013 ASX Announcement ECQ: CYNATA INCORPORATED SIGNS FOUNDATION AGREEMENT The Board of Eco Quest advises that its associate company, Cynata Inc, has signed a Foundation License Agreement (FLA)
More informationGenentech, Inc., its research partners, collaborators, assignees, licensees or designees. Invitation to Participate
CONSENT AND RESEARCH AUTHORIZATION TO DONATE BLOOD AND TISSUE SAMPLES FOR FUTURE RESEARCH PURPOSES YALE UNIVERSITY SCHOOL OF MEDICINE YALE-NEW HAVEN HOSPITAL 200 FR. 4 Study Title: An Open-Label, Phase
More informationInnovation and Technology in Breast Cancer 2018 A research initiative from Breast Cancer Foundation NZ.
Request for Proposals Innovation and Technology in Breast Cancer 2018 A research initiative from Breast Cancer Foundation NZ. Overview Breast Cancer Foundation NZ (BCFNZ) is committed to funding research
More informationLETTER OF INTENT Early Phase Clinical Trials 2018
LETTER OF INTENT Early Phase Clinical Trials 2018 Applications are being accepted on a rolling basis. This Letter of Intent is an example only. Do not complete this paper application. Please submit the
More informationClinical Research at MSU
Financial Administration Development Program: Clinical Research at MSU Kristen Burt, Office of Regulatory Affairs (ORA) Sharon Schooley, Clinical & Translational Sciences Institute (CTSI) February 24,
More informationFULL SUBMISSION DEADLINE: August 31 st, 2018
Funding Opportunity for Pilot & Feasibility Projects through the University of Chicago's NIDDK/NIH-Sponsored Digestive Diseases Research Core Center (DDRCC) ****Interested applicants should contact Drs.
More informationLA RICERCA TELETHON PER LE MALATTIE RARE TELETHON RESEARCH ON RARE DISEASES
LA RICERCA TELETHON PER LE MALATTIE RARE TELETHON RESEARCH ON RARE DISEASES Francesca Pasinelli Direttore Generale 3 Congresso Nazionale SIFaCT Roma, 9 ottobre 2015 About Telethon Fondazione Telethon is
More informationRealizing the Future that Regenerative Medicine Will Open
470 Hitachi Review Vol. 65 (2016), No. 9 Featured Articles Realizing the Future that Regenerative Medicine Will Open Shizu Takeda, Ph.D. OVERVIEW: Regenerative medicine is an innovative approach to medicine
More informationCell Therapy Services Your Product. Our Passion.
Pharma&Biotech Cell Therapy Services Your Product. Our Passion. Complete Portfolio of Services for cgmp Manufacturing of Cell-based Products Pharma&Biotech Cell Therapy Services for cgmp Manufacturing
More informationNIH Grantsmanship Elements of Success. When to Submit Your Application? How does NIH Support Research? What Should Be in the Application?
NIH Grantsmanship Elements of Success s of Health Office of the Director on Aging on Alcohol Abuse and Alcoholism of Allergy and Infectious Diseases of Arthritis and Musculoskeletal and Skin Diseases National
More informationDMTC Technology Readiness Levels Guideline
Technology Readiness Levels Technology Readiness Levels (TRLs) are used as standardised numerical indicators of the level of maturity of a technology. The standard TRL definitions are given in Table 1.
More information11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationTHE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION
THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION William S. Dalton, PhD, MD AACR April 17, 2016 Designing a Federated Model To Support Research & Healthcare Offices
More informationSection I: Pharmaceuticals and Medical Devices
SUPPLEMENT on HEALTHCARE INNOVATION Visionary Goals and Recommendations 51th Japan-U.S. Business Conference Japan-U.S. Business Council / U.S.-Japan Business Council November 14, 2014 The R&D-based pharmaceutical
More informationTHRIVE NETWORK REQUEST FOR PROPOSALS
THRIVE NETWORK REQUEST FOR PROPOSALS The THRIVE Network is an initiative of United Way of Madison County, focused on improving the financial lives of individuals and families who have limited wealth, income
More informationEarlier Access to Medicines Early Access to Medicines Scheme and Adaptive Licensing pilot
Earlier Access to Medicines Early Access to Medicines Scheme and Adaptive Licensing pilot World Stem Cells & Regenerative Medicine 2014 Dr Daniel O Connor Disclaimer The views expressed do not necessarily
More informationGuidance on Request for Information on Rapid Response Platform Technologies for Epidemic Preparedness
Guidance on Request for Information on Rapid Response Platform Technologies for Epidemic Preparedness Purpose of this request for information The Bill & Melinda Gates Foundation (BMGF; also referred to
More informationMAKING OUTCOME-BASED PAYMENTS A REALITY IN THE NHS RESEARCH STUDY: PHASE INTRODUCTION. Research Brief
MAKING OUTCOME-BASED PAYMENTS A REALITY IN THE NHS RESEARCH STUDY: PHASE 1 1.0 INTRODUCTION Cancer Research UK (CRUK) believes cancer patients should have access to the best, evidence-based innovative
More informationRUCDR Infinite Biologics
RUCDR Infinite Biologics ips DISTRIBUTION MATERIAL TRANSFER AGREEMENT For use by REPOSITORY to Transfer CRM ips CELLS to REPOSITORY CUSTOMERS [Articles 1.3, 3.5] Induced Pluripotent Stem (ips) Cell Material
More informationOur job today Enlist you to help us cross the Translational Divide between the lab bench and the patient s bedside Demonstrate that this will
Bench Bedside Our job today Enlist you to help us cross the Translational Divide between the lab bench and the patient s bedside Demonstrate that this will be done in our Kimmel Cancer Center at Hopkins,
More informationWebinar: Knowledge-based approaches to decreasing clinical attrition rates
Webinar: Knowledge-based approaches to decreasing clinical attrition rates Speakers: Dr. Richard K. Harrison Gavin Coney Teresa Fishburne May 2018 2 Clarivate Analytics is the global leader in providing
More informationSubmission Limitations: Emory University may submit only 1 application for this program
National Institutes of Health NIAMS Rheumatic Diseases Research Core Centers (P30) Website: http://grants.nih.gov/grants/guide/rfa-files/rfa-ar-12-002.html Agency Deadline: February 1, 2012 (Letters of
More informationCell Processing Workstation. In Situ Laser-Mediated Cell Purification and Processing
LEAP Cell Processing Workstation Cell Processing Workstation In Situ Laser-Mediated Cell Purification and Processing Expanding the Capabilities of Cell Processing Consistent, High-Yield, High-Purity Processing
More informationOFFICIAL COMPETITION RULES
When: June 7, 2019 9:00 AM-5:00 PM Where: The Global Center for Health Innovation, Cleveland, OH (Application portal will open January 2019) OFFICIAL COMPETITION RULES OVERVIEW: BioEnterprise (Organizer)
More informationFor personal use only
ASX/Media Release 31 October 2017 Botanix Pharmaceuticals 4C Quarterly Cash Flow Report Highlights for the quarter ending 30 September 2017: Completed Phase 1 safety, tolerability and pharmacokinetics
More informationHarnessing the Power of Nanotechnology for Human Health: The NIH/NIEHS Perspective
Harnessing the Power of Nanotechnology for Human Health: The NIH/NIEHS Perspective Sally Tinkle, Ph.D. National Institute of Environmental Health Sciences NIH Mission NIH is the steward of medical and
More informationCustomer Billing and Revenue Data Warehouse Design and Implementation Project
REQUEST FOR PROPOSAL Customer Billing and Revenue Data Warehouse Design and Implementation Project This Request for Proposal (RFP) is being issued to evaluate and select a qualified vendor to implement
More informationREQUEST FOR APPLICATIONS. AISP Learning Community: Integrated Data System Training & Technical Assistance Program. Issued: April 3, 2017
REQUEST FOR APPLICATIONS AISP Learning Community: Integrated Data System Training & Technical Assistance Program Issued: April 3, 2017 IMPORTANT INFORMATION Purpose: Applicant s Webinar (optional) Applications
More informationRegulation of Cell and Gene Therapy Products in Canada
Regulation of Cell and Gene Therapy Products in Canada Canadian Blood and Bone Marrow Transplant Group June 8, 2018 Nadine Kolas, PhD Senior Policy Analyst Blood, Cells, Tissues and Organs Biologics and
More information11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationLETTER OF INTENT Rapid Response: Canada 2019 Parkinson s & Related Diseases
LETTER OF INTENT Rapid Response: Canada 2019 Parkinson s & Related Diseases DEADLINE: Wednesday, August 1, 2018, 2:00pm EDT Applicants will be notified of Proposal invitations in September 2018. This Letter
More informationMedical Device Non-Dilutive Funding: Trends & Opportunities
FreeMindGroup FreeMind Group @FreeMindGrp Medical Device Non-Dilutive Funding: Trends & Opportunities B. Stuart Jacobowitz Sr. Director, Business Development December 6, 2017 FreeMind Group FreeMind Group,
More informationResearch Job Summaries
Job Summaries Job 32713 32712 32711 32613 32612 32611 32516 32515 32514 32513 32512 32511 Chief Officer Deputy Chief Officer Senior Officer Officer The Chief Officer (CRO) serves as an integral member
More informationPerspective: Convergence of CLIA and FDA Requirements A Rational Shift in the Regulatory Paradigm
Perspective: Convergence of CLIA and FDA Requirements A Rational Shift in the Regulatory Paradigm Planning for Efficiencies of Data, Resources, and Timelines A PRECISION BRIEF Introduction As precision
More informationEmerging Trends in Regulatory Outsourcing WHITE PAPER.
WHITE PAPER www.makrocare.com/consulting You are not alone in the quest for bringing your products to market and improve the quality of the life for millions! MakroCare brings you the insight on how a
More informationProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011
ProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011 1 Forward Looking Statement / Copyright notice / Disclaimer Forward Looking Statement This presentation contains forward-looking
More informationPluristem Issues Letter to Shareholders
Pluristem Issues Letter to Shareholders HAIFA, Israel, January 30, 2014 -- Pluristem Therapeutics Inc. (NASDAQCM: PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today issued a
More informationExpanded Access and the Individual Patient IND
Expanded Access and the Individual Patient IND Research Wednesdays April 26, 2017 Erika Segear Johnson, PhD, RAC Associate Director of Regulatory Affairs Office of Regulatory Affairs and Quality Office
More informationDr. Earl Dye CMC/GMP Considerations for Expedited Development Programs
Dr. Earl Dye CMC/GMP Considerations for Expedited Development Programs Earl Dye is Director of Technical Regulatory Policy in Genentech s Washington, DC Regulatory Affairs Office, and is the FDA Liaison
More informationAgenda: Opportunities in Developing Orphan Drug Products. Mukesh Kumar, PhD, RAC
This Seminar is Brought to you by Amarex Clinical Research Washington DC metro area A Product Development Services Company From Lab to Market Approval FDA Meetings Global Regulatory Submissions Global
More informationCMC Considerations for Stem Cell-based. Donald W. Fink, Jr., Ph.D.
Food and Drug Administration Center for Biologics Evaluation and Research CMC Considerations for Stem Cell-based Products Donald W. Fink, Jr., Ph.D. Phone: (301) 827-5153 E-Mail: donald.fink@fda.hhs.gov
More informationRequest for Projects for Wake Forest Brain Tumor SPORE Application
1 Request for Projects for Wake Forest Brain Tumor SPORE Application This RFA is for three types of projects that will be taken into consideration for inclusion in the Wake Forest Brain Tumor Specialized
More informationPatient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies WWW.ISSCR.ORG WWW.CLOSERLOOKATSTEMCELLS.ORG Patient Handbook on Stem Cell Therapies Introduction We have all heard about the extraordinary promise that stem cell
More informationLETTER OF INTENT Rapid Response: Canada 2019 Parkinson s & Related Diseases Round 2
LETTER OF INTENT Rapid Response: Canada 2019 Parkinson s & Related Diseases Round 2 DEADLINE: March 13, 2019, 2:00pm EDT Applicants will be notified of Proposal invitations in May 2019 This Letter of Intent
More informationLETTER OF INTENT Rapid Response: Canada 2019 Parkinson s & Related Diseases Round 2
LETTER OF INTENT Rapid Response: Canada 2019 Parkinson s & Related Diseases Round 2 DEADLINE: May 15, 2019, 2:00pm EDT Applicants will be notified of Proposal invitations in August 2019 This Letter of
More informationMultiple Myeloma Research Foundation 2014 Research Fellow Award Program Guidelines
Multiple Myeloma Research Foundation 2014 Research Fellow Award Program Guidelines Program Description: MULTIPLE MYELOMA RESEARCH FOUNDATION 2014 RESEARCH FELLOW AWARD The Multiple Myeloma Research Foundation
More informationHOW TO IDENTIFY & PRIORITIZE TRIAL STAKEHOLDERS
HOW TO IDENTIFY & PRIORITIZE TRIAL STAKEHOLDERS The following editable chart can help you, the trial designer, identify and prioritize the stakeholders you may need to engage to ensure the success of your
More informationVertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis
Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis -Collaboration to explore use of mrna Therapeutics to treat the underlying cause of CF
More informationPolicy Appendix IV: DRCR.net Industry Collaboration Policies Version 5.0, February 2, 2009
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 DRCR.net is committed to: performing rigorous multi-center clinical
More informationResearch Opportunities Program Guidelines
July 2015 2015-16 Research Opportunities Program Guidelines Prevention Office Ministry of Labour Table of Contents 1. General Information...2 2. Priority Areas...2 3. Funding Parameters...6 4. Application
More informationThe Role of the IRB in Clinical Trials: What Patients and Families Need to Know. Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation
The Role of the IRB in Clinical Trials: What Patients and Families Need to Know Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation 1 CAC2 Values v Put the children and their families first in
More informationThe NIH Peer Review System
The NIH Peer Review System Dolores J. Lamb Director, Center for Reproductive Medicine, Lester and Sue Smith Chair in Urologic Research Vice-Chairman for Research and Professor in the Scott Department of
More information2015 Research Trainee Program Competition for Post-Doctoral Fellowship Awards EVALUATION CRITERIA FOR REVIEWERS
2015 Research Trainee Program Competition for Post-Doctoral Fellowship Awards EVALUATION CRITERIA FOR REVIEWERS VERSION 1 LAST UPDATED: JANUARY 28, 2015 Note to ALL Reviewers: Read all assigned applications
More informationPolicy Appendix IV: DRCR.net Industry Collaboration Policies Version 6.0, August 2, 2017
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 DRCR.net is committed to: performing rigorous multi-center clinical
More information